ArticleBMC infectious diseases2024
Prevalence and mechanisms of aminoglycoside resistance among drug-resistant Pseudomonas aeruginosa clinical isolates in Iran.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of antimicrobial resistance in equine-associated Pseudomonas aeruginosa: a systematic review and meta-analysis.BMC veterinary research · 2025Pooled it
- Pseudomonas aeruginosa ST4936 with extensive antibacterial drug resistance and virulence determinants from ureteral stent biofilms: whole-genome insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Phenotypic and genotypic antimicrobial resistance profiles of gram-positive cocci and non-fermenting gram-negative rods.Scientific reports · 2026Article
- Molecular and Computational Insights of Novel Mutations in Aminoglycoside-Modifying Genes of P. aeruginosa.Molecular biotechnology · 2026Article
- Genetic diversity, detection of virulence genes and high prevalence of blaMolecular biology reports · 2026Article
- Aminoglycoside Resistance Among Clinical Bacterial Isolates in Sétif, Algeria: Epidemiology, Multidrug Resistance, and Virulence Features.Antibiotics (Basel, Switzerland) · 2026Article
- Genotype-Phenotype Links Between Aminoglycoside-Modifying Enzymes and Aminoglycoside MICs in Aminoglycoside-ResistantMicroorganisms · 2026Article
- Isolation and characterization of a lytic phage and its efficacy against multi-drug resistant strains of pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Immunological and molecular detection of biofilm formation and antibiotic resistance genes ofIranian journal of microbiology · 2025Article
- Evaluation of Biofilm Formation, Alginate Production, Pattern of Drug Resistance, and the Presence of Efflux PumpTanaffos · 2025Article
- Whole-Genome Sequencing of Resistance, Virulence and Regulation Genes in Extremely Resistant Strains ofMedical sciences (Basel, Switzerland) · 2025Article
- Recombinant Antimicrobial Peptides (rAMPs); Potential Applications in Medicine and Veterinary Medicine: A Review.Iranian journal of biotechnology · 2024Review
- Phenotypic and genotypic identification of class C and D β-lactamases in clinical isolates ofHealth science reports · 2024Article
- Resistome in the indoor dust samples from workplaces and households: a pilot study.Frontiers in cellular and infection microbiology · 2024Article
- Exploring the antimicrobial potential of pomegranate peel extracts (PPEs): Extraction techniques and bacterial susceptibility.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAminoglycosides have been a cornerstone of the treatment of nosocomial infections caused by Pseudomonas aeruginosa for over 80 years. However, escalating emergence of resistance poses a significant challenge. Therefore, this study aimed to investigate the prevailing patterns of aminoglycoside resistance among clinical isolates of P. aeruginosa in Iran; as well as the underlying resistance mechanisms observed in patients referred to Ardabil hospitals.
methodsA total of 200 isolates from five hospitals were evaluated. The resistance profiles of P. aeruginosa isolates to tobramycin, amikacin, and netilmicin were determined using the disk diffusion method. The capacity of aminoglycoside-resistant isolates to form biofilms was assessed through a phenotypic assay, and the results were confirmed using the gene amplification technique. The presence of genes associated with aminoglycoside resistance was detected using polymerase chain reaction (PCR). Quantitative reverse transcription PCR (qRT-PCR) was performed to measure the expression levels of genes encoding the MexXY-OprM efflux pump and PhoPQ two-component system (TCS).
resultsThe prevalence of aminoglycoside-resistant P. aeruginosa isolates was 48%, with 94.7% demonstrating multidrug resistance (MDR). All aminoglycoside-resistant P. aeruginosa strains exhibited biofilm-forming capabilities and harbored all the genes associated with biofilm production. Among the nine genes encoding 16S rRNA methylase and aminoglycoside-modifying enzymes, three genes were detected in these isolates: aac(6')-Ib (85.4%), ant(2'')-Ia (18.7%), and aph(3')-VI (3.1%). Additionally, all aminoglycoside-resistant P. aeruginosa isolates carried mexY and phoP genes, although the expression levels of mexY and phoP were 75% and 87.5%, respectively.
conclusionGiven the considerably high prevalence of aminoglycoside-resistant P. aeruginosa strains, urgent measures are warranted to transition towards the use of novel aminoglycosides and to uphold vigilant surveillance of resistance patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.